Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
Loss of nigral dopamine neurons in Parkinson's disease induces abnormal activation of glutamate systems in the basal ganglia. The purpose of this study was to assess these changes in the lentiform nucleus using MRS with optimized glutamate sensitivity (TE-averaged method). Ten patients with Parkinson's disease and 10 healthy controls were examined. Compared with healthy controls, no significant differences in glutamate were measured in patients, but a trend to lower total creatine was observed.
Kickler
Nils
N
INSERM, U594, Neuroimagerie fonctionnelle et métabolique, Grenoble, France. Nils.Kickler@ujf-grenoble.fr
Krack
Paul
P
Fraix
Valérie
V
Lebas
Jean-François
JF
Lamalle
Laurent
L
Durif
Franck
F
Krainik
Alexandre
A
Rémy
Chantal
C
Segebarth
Christoph
C
Pollak
Pierre
P
D000978:Antiparkinson Agents / Q000627:therapeutic use; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism*; D003401:Creatine / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism*; D005973:Glutamine / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D009682:Magnetic Resonance Spectroscopy; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D012016:Reference Values; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000978:Antiparkinson Agents; D005973:Glutamine; D001224:Aspartic Acid; D018698:Glutamic Acid; D007980:Levodopa; D005680:gamma-Aminobutyric Acid; C000179:N-acetylaspartate; D003401:Creatine